ROR1 and melanoma: These effects suggest that a decline in phospho-ROR1 activation following rhARSB, CHST15 siRNA, or Cirmtuzumab provides a pathway that coordinates a tyrosine-kinase-like surface receptor with chondroitin sulfate and melanoma apoptosis.